3-[4-(4-nitrophenyl)-piperazin-1-yl]-propionitrile | 743449-17-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-[4-(4-nitrophenyl)-piperazin-1-yl]-propionitrile
• 英文别名: 3-[4-(4-Nitrophenyl)piperazin-1-yl]propanenitrile
• CAS: 743449-17-4
• 化学式: C₁₃H₁₆N₄O₂
• 分子量: 260.296
• InChiKey: MQBPCRCXGBYTFX-UHFFFAOYSA-N

物化性质

• 熔点：
  92-94 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  481.6±45.0 °C(Predicted)
• 密度：
  1.227±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  76.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-[4-(4-nitrophenyl)-piperazin-1-yl]-propionitrile 在 sodium azide 、 三乙胺盐酸盐 作用下， 以 甲苯 为溶剂， 反应 48.0h， 以86.32%的产率得到1-(4-nitrophenyl)-4-[2-(1H-tetrazol-5-yl)-ethyl]-piperazine
  参考文献：
  名称：

  Optically active antifungal azoles: synthesis and antifungal activity of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-{2-[4-aryl-piperazin-1-yl]-ethyl}-tetrazol-2-yl/1-yl)-1-[1,2,4]-triazol-1-yl-butan-2-ol

  摘要：

  A series of (2 R, 3S)-2-(2,4-difluorophenyl)-3-(5-{2-[4-aryl-piperazin-1-yl]-ethyl}-tetrazo-2-yl)-1-[1,2,4]-triazol-1-yl-butan-2-ol (11a-n) and (2R,3S)-2-(2,4-difluorophenyl)-3-(5-{2-[4-aryl-piperazin-1-yi]-ethyl}-tetrazole-1-yl)-1-[1,2,4]-triazol-1-yl-butan-2-ol (12a-n) has been synthesized. The antifungal activity of compounds was evaluated by in vitro agar diffusion and broth dilution assay. Compounds 11d and its positional isomer 12d having 3-trifluoromethyl substitution on the phenyl ring of piperazine demonstrated significant antifungal activity against variety of fungal cultures (Candida spp. C. neoformans and Aspergillus spp.). The compound 12d showed MIC value of 0.12mug/mL for C. albicans, C albicans V-01-191A-261 (resistant strain); 0.25mug/mL for C tropicalis, C parapsilosis ATCC 22019 and C krusei and MIC value of 0.5 mug/mL for C glabrata, C krusei ATCC 6258, which is comparable to itraconazole and better than fluconazole. Further, compound 11d showed significant activity (MIC; 0.25-0.5 mug/mL) against Candida spp. and strong anticryptococcal activity (MIC; 0.25 mug/mL) against C neoformans. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.02.014
• 作为产物：
  描述：

  1-(4-硝基苯基)哌嗪 、 丙烯腈 在 single-walled carbon nanotube-triethylammonium hydrogen phosphate ionic liquid 作用下， 反应 0.02h， 以97%的产率得到3-[4-(4-nitrophenyl)-piperazin-1-yl]-propionitrile
  参考文献：
  名称：

  Single-walled Carbon Nanotube-triethylammonium Ionic Liquid as a New Catalytic System for Michael Reaction

  摘要：

  开发了一种新型高效的催化方法，用于胺/硫醇与更高产物收率的aza/thia-Michael加成反应。将单壁碳纳米管（SWCNT）与三乙基磷酸氢铵（TEAP）离子液体（IL）结合可作为催化剂。我们利用拉曼光谱学来深入了解IL与SWCNT之间的相互作用。通过SWCNT的拉曼D带和G带强度比增加以及波长位移确认了SWCNT与TEAP之间的相互作用。此外，通过使用扫描电子显微镜（SEM）确定了TEAP和SWCNT复合材料的形貌。使用巴基凝胶作为Michael反应的催化剂的关键优势在于缩短反应时间并提高产物收率。

  DOI：

  10.5012/bkcs.2014.35.10.3035

文献信息

• Triethylammonium acetate (TEAA): a recyclable inexpensive ionic liquid promotes the chemoselective aza- and thia-Michael reactions
  作者：Akhilesh K. Verma、Pankaj Attri、Varun Chopra、Rakesh K. Tiwari、Ramesh Chandra

  DOI：10.1007/s00706-008-0886-4

  日期：2008.9

  A new, highly efficient, inexpensive, recyclable, mild, convenient, and green protocol for chemoselective aza/thia- Michael addition reactions of amines/thiols to α,β - unsaturated compounds using triethylammonium acetate ( TEAA ) ionic liquid was developed. The catalyst can be recycled ten times and obviate the need for toxic and expensive catalysts.

  用于化学选择性氮杂/硫杂一种新的，高效率的，廉价的，可回收，轻度，方便，和绿色协议 迈克尔 的胺/硫醇到α，β加成反应 - 使用三乙基乙酸铵（不饱和化合物 TEAA ）离子液体被开发。该催化剂可以循环使用十次，从而消除了对有毒和昂贵催化剂的需求。
• TRICYCLIC INHIBITORS OF KINASES
  申请人：Tong Yunsong

  公开号：US20120220572A1

  公开（公告）日：2012-08-30

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein X, Y, Z, R 3 and R 4 are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

  本发明涉及式(I)的化合物或药用可接受的盐，其中X、Y、Z、R3和R4在描述中有定义。本发明还涉及含有上述化合物的组合物，用于抑制wee-1等激酶，并治疗癌症等疾病的方法。
• Dihydropyrazolopyrimidinone derivatives
  申请人：Sagara Takeshi

  公开号：US20070254892A1

  公开（公告）日：2007-11-01

  The invention relates to compounds of a general formula (I): wherein Ar 1 is an optionally-substituted aryl or heteroaromatic group; R 1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 3 is a hydrogen atom or a lower alkyl group; R 4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R 1k )R 1m ; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

  该发明涉及一般式（I）的化合物，其中Ar1是可选择取代的芳基或杂环芳基；R1是可选择取代的较低烷基、较低烯烃基、较低炔烃基或环状较低烷基基团，或是具有取代基的芳基、芳基烷基或杂环芳基；R2是氢原子、较低烷基基团、较低烯烃基团或较低炔烃基团，或是具有取代基的芳基、芳基烷基或杂环芳基；R3是氢原子或较低烷基基团；R4是氢原子、卤素原子、羟基、较低烷基基团或—N(R1k)R1m基团；T和U是氮原子或亚甲基基团等。该发明的化合物具有出色的Weel激酶抑制作用，因此在药物领域中特别适用于治疗各种癌症。
• DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES
  申请人：Sagara Takeshi

  公开号：US20110189130A1

  公开（公告）日：2011-08-04

  The invention relates to compounds of a general formula (I): wherein Ar 1 is an optionally-substituted aryl or heteroaromatic group; R 1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 3 is a hydrogen atom or a lower alkyl group; R 4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R 1k )R 1m ; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

  本发明涉及一般式(I)的化合物：其中Ar1是可选取代的芳基或杂环芳基基团；R1是可选取代的低碳基、低烯基、低炔基或环-低碳基基团，或是带有取代基的芳基、芳基烷基或杂环芳基基团；R2是氢原子、低碳基、低烯基或低炔基，或是带有取代基的芳基、芳基烷基或杂环芳基基团；R3是氢原子或低碳基；R4是氢原子、卤素原子、羟基、低碳基或—N(R1k)R1m基团；T和U是氮原子或甲基基团等。该发明的化合物具有出色的Weel激酶抑制作用，因此在药物领域，特别是治疗各种癌症方面非常有用。
• Dihydropyrazolopyrimidinone Derivatives
  申请人：Sakamoto Toshihiro

  公开号：US20100063024A1

  公开（公告）日：2010-03-11

  The invention relates to compounds of a general formula (I): wherein Ar 1 is an optionally-substituted aryl or heteroaromatic group; R 1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 3 is a hydrogen atom or a lower alkyl group; R 4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R 1k )R 1m ; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

  本发明涉及一般式（I）的化合物：其中Ar1是可选取取代基的芳基或杂环芳基基团；R1是可选取取代基的低碳基、低烯基、低炔基或环低碳基基团，或是带取代基的芳基、芳基烷基或杂环芳基基团；R2是氢原子、低碳基、低烯基或低炔基，或是带取代基的芳基、芳基烷基或杂环芳基基团；R3是氢原子或低碳基；R4是氢原子、卤素原子、羟基、低碳基或-N（R1k）R1m基团；T和U是氮原子或甲基烷基等。本发明的化合物具有出色的Weel激酶抑制作用，因此在药物领域中特别适用于治疗各种癌症。